Literature DB >> 18442296

Trends in kidney transplantation over the past decade.

Greg Knoll1.   

Abstract

Kidney transplantation offers patients with end-stage renal disease the greatest potential for increased longevity and enhanced quality of life; however, the demand for kidneys far exceeds the available supply. This has led to an increase in the number of people on waiting lists and an increase in waiting time. In the US, the overall median wait time was 2.85 years in 2004. The projected median waiting time for adult patients awaiting a deceased donor kidney in 2006 is 4.58 years. The renal transplant community has pursued multiple avenues in an attempt to increase the donor pool, but this remains a major challenge. In the last decade, the number of live donor kidney transplants performed in the US and Canada has doubled and represents just over 40% of all donor kidneys. Among deceased donor kidneys, the largest percentage increases were seen in expanded criteria donor and donation after cardiac death kidneys. In the last decade, the age distribution among donors, and among patients on waiting lists or receiving a renal transplant, has shifted towards older age groups. There have been dramatic shifts in baseline immunosuppression with increased usage of induction agents and the nearly universal replacement of azathioprine by mycophenolate. Additionally, tacrolimus use has increased from 13% to 79% at discharge, while ciclosporin (cyclosporine) use has fallen from 76% to 15%. Although 1-year graft survival rates are excellent, only modest improvements have been observed in long-term graft survival rates in the last decade. Thus, efforts have shifted from improving early graft outcomes to altering the natural course of late graft failure. Death of transplant recipients from cardiovascular disease, infection and cancer remains an important limitation in kidney transplantation. Continued success in kidney transplantation will require increased numbers of donors, both living and deceased, as well as reduction in the primary causes of late transplant loss, namely premature patient death with a functioning graft and chronic allograft nephropathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18442296     DOI: 10.2165/00003495-200868001-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  24 in total

1.  ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends.

Authors:  Aileen Grassmann; Simona Gioberge; Stefan Moeller; Gail Brown
Journal:  Nephrol Dial Transplant       Date:  2005-10-04       Impact factor: 5.992

2.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors:  Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

Review 3.  Malignancy after transplantation.

Authors:  Joseph F Buell; Thomas G Gross; E Steve Woodle
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

4.  Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients.

Authors:  Barry D Kahan; Yarkin K Yakupoglu; Linda Schoenberg; Richard J Knight; Stephen M Katz; Deijan Lai; Charles T Van Buren
Journal:  Transplantation       Date:  2005-09-27       Impact factor: 4.939

5.  Racial disparities in living kidney donation: is there a lack of willing donors or an excess of medically unsuitable candidates?

Authors:  Shayna L Lunsford; Kit S Simpson; Kenneth D Chavin; Kerry J Menching; Lucia G Miles; Lilless M Shilling; Gilbert R Smalls; Prabhakar K Baliga
Journal:  Transplantation       Date:  2006-10-15       Impact factor: 4.939

6.  Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.

Authors:  Valter Duro Garcia; José Luz Bonamigo Filho; Jorge Neumann; Laura Fogliatto; Anna Maria Geiger; Clotilde Druck Garcia; Vivianne Barros; Elizete Keitel; Antonio Eduardo Bittar; Auri Ferrera des Santos; Sergio Roithmann
Journal:  Transpl Int       Date:  2003-02-13       Impact factor: 3.782

7.  Kidneys from deceased donors: maximizing the value of a scarce resource.

Authors:  Herwig-Ulf Meier-Kriesche; Jesse D Schold; Robert S Gaston; Jonas Wadstrom; Bruce Kaplan
Journal:  Am J Transplant       Date:  2005-07       Impact factor: 8.086

8.  Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.

Authors:  Timothy Mathew; Henri Kreis; Peter Friend
Journal:  Clin Transplant       Date:  2004-08       Impact factor: 2.863

9.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.

Authors:  Hallvard Holdaas; Bengt Fellström; Alan G Jardine; Ingar Holme; Gudrun Nyberg; Per Fauchald; Carola Grönhagen-Riska; Søren Madsen; Hans-Hellmut Neumayer; Edward Cole; Bart Maes; Patrice Ambühl; Anders G Olsson; Anders Hartmann; Dag O Solbu; Terje R Pedersen
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.

Authors:  Josep M Campistol; Alex Gutierrez-Dalmau; J Vicente Torregrosa
Journal:  Transplantation       Date:  2004-03-15       Impact factor: 4.939

View more
  43 in total

1.  BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs.

Authors:  Emma M Carrington; Ingela B Vikstrom; Amanda Light; Robyn M Sutherland; Sarah L Londrigan; Kylie D Mason; David C S Huang; Andrew M Lew; David M Tarlinton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 2.  Transplantation immunology: solid organ and bone marrow.

Authors:  Javier Chinen; Rebecca H Buckley
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

3.  Risk factors for fracture in adult kidney transplant recipients.

Authors:  Kyla L Naylor; Guangyong Zou; William D Leslie; Anthony B Hodsman; Ngan N Lam; Eric McArthur; Lisa-Ann Fraser; Gregory A Knoll; Jonathan D Adachi; S Joseph Kim; Amit X Garg
Journal:  World J Transplant       Date:  2016-06-24

Review 4.  Psychiatric issues in pediatric organ transplantation.

Authors:  Margaret L Stuber
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2010-04

5.  Effects of a clinical pathway on quality of care in kidney transplantation: a non-randomized clinical trial.

Authors:  Matthias Schwarzbach; Roderich Bönninghoff; Katrin Harrer; Johannes Weiss; Christof Denz; Peter Schnülle; Rainer Birck; Stefan Post; Ulrich Ronellenfitsch
Journal:  Langenbecks Arch Surg       Date:  2010-01       Impact factor: 3.445

6.  Select phytochemicals suppress human T-lymphocytes and mouse splenocytes suggesting their use in autoimmunity and transplantation.

Authors:  Shazaan Hushmendy; Lalithapriya Jayakumar; Amy B Hahn; Devang Bhoiwala; Dipti L Bhoiwala; Dana R Crawford
Journal:  Nutr Res       Date:  2009-08       Impact factor: 3.315

Review 7.  The promise of organ and tissue preservation to transform medicine.

Authors:  Sebastian Giwa; Jedediah K Lewis; Luis Alvarez; Robert Langer; Alvin E Roth; George M Church; James F Markmann; David H Sachs; Anil Chandraker; Jason A Wertheim; Martine Rothblatt; Edward S Boyden; Elling Eidbo; W P Andrew Lee; Bohdan Pomahac; Gerald Brandacher; David M Weinstock; Gloria Elliott; David Nelson; Jason P Acker; Korkut Uygun; Boris Schmalz; Brad P Weegman; Alessandro Tocchio; Greg M Fahy; Kenneth B Storey; Boris Rubinsky; John Bischof; Janet A W Elliott; Teresa K Woodruff; G John Morris; Utkan Demirci; Kelvin G M Brockbank; Erik J Woods; Robert N Ben; John G Baust; Dayong Gao; Barry Fuller; Yoed Rabin; David C Kravitz; Michael J Taylor; Mehmet Toner
Journal:  Nat Biotechnol       Date:  2017-06-07       Impact factor: 54.908

8.  Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

Authors:  Brenda C M de Winter; Teun van Gelder; Ferdi Sombogaard; Leslie M Shaw; Reinier M van Hest; Ron A A Mathot
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

9.  Gene Transfer to Mouse Kidney In Vivo.

Authors:  C J Rocca; S Cherqui
Journal:  Methods Mol Biol       Date:  2019

Review 10.  Immunosuppressant utilization and cardiovascular complications among Chinese patients after kidney transplantation: a systematic review and analysis.

Authors:  Yan Liu; Mao-Sheng Yang; Jian-Yong Yuan
Journal:  Int Urol Nephrol       Date:  2012-10-11       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.